CoChat

Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study

Open access
Fishbane, Steven, El-Shahawy, Mohamed A., Pecoits-Filho, Roberto, Van, Bui Pham, Houser, Mark T., Frison, Lars, Little, Dustin J., Guzman, Nicolas J., Pergola, Pablo E. · 2021 · Journal of the American Society of Nephrology
Cited by 184

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Significance Statement: Anemia is untreated in many patients with non–dialysis-dependent CKD. Barriers to the use of current anemia therapies among such patients include parenteral administration that may require a medical visit, a requirement for iron repletion, and potentially increased risk of cardiovascular events. In a phase 3 placebo-controlled international study, the authors compared roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, with placebo for the treatment of anemia of non–dialysis-dependent CKD. They report that roxadustat was statistically superior to placebo in increasing hemoglobin and reduced the need for red blood cell transfusion. The drug also was generally well tolerated and had an adverse event profile comparable to placebo. These findings indicate that roxadustat may be clinically useful for the oral management of anemia in patients with non–dialysis-dependent CKD. Background: Current anemia therapies for patients with non–dialysis-dependent CKD may require injection and medical visits. Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis and improves iron homeostasis. Methods: In this double-blind phase 3 study, we randomized patients with non–dialysis-dependent CKD stages 3–5 and hemoglobin <10.0 g/dl (1:1) to thrice-weekly 70-mg oral roxadustat or placebo. Doses were titrated throughout the study based on hemoglobin levels. The primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28–52 versus placebo, irrespective of rescue therapy use. We assessed patients for adverse events. Results: The study included 2781 patients, 1393 who received roxadustat and 1388 who received placebo. Mean baseline hemoglobin was 9.1 g/dl for both groups. The mean change in hemoglobin from baseline was 1.75 g/dl (95% confidence interval [95% CI], 1.68 to 1.81) with roxadustat versus 0.40 g/dl (95% CI, 0.33 to 0.47) with placebo, (P<0.001). Among 411 patients with baseline elevated high-sensitivity C-reactive protein, mean change in hemoglobin from baseline was 1.75 g/dl (95% CI, 1.58 to 1.92) with roxadustat versus 0.62 g/dl (95% CI, 0.44 to 0.80) with placebo, (P<0.001). Roxadustat reduced the risk of red blood cell transfusion by 63% (hazard ratio, 0.37; 95% CI, 0.30 to 0.44). The most common adverse events with roxadustat and placebo, respectively, were ESKD (21.0% versus 20.5%), urinary tract infection (12.8% versus 8.0%), pneumonia (11.9% versus 9.4%), and hypertension (11.5% versus 9.1%). Conclusions: Roxadustat effectively increased hemoglobin in patients with non–dialysis-dependent CKD and reduced the need for red blood cell transfusion, with an adverse event profile comparable to that of placebo. Clinical Trial registry name and registration number: Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With CKD, Not on Dialysis, NCT02174627

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2020081150

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 184

Metadata

Authors
Fishbane, S., El-Shahawy, M. A., Pecoits-Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pergola, P. E.
Venue
Journal of the American Society of Nephrology
Published
2021-02-10
Volume
32
Issue
3
Pages
737-755
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W3128080784
Cited by
184
References
7
FWCI
18.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. https://app.cochat.ai/papers/10.1681/asn.2020081150
The paper
Fishbane, S., El-Shahawy, M. A., Pecoits-Filho, R., Van, B. P., Houser, M. T., Frison, L., Little, D. J., Guzman, N. J., & Pergola, P. E. (2021). Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2020081150

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.